Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver

Li,Maoqin; Sun,Jingxi; Li,Jiaqiong; Shi,Zaixiang; Xu,Jiyuan; Lu,Bo; Cheng,Shuli; Xu,Yanjun; Wang,Xiaomeng; Zhang,Xianjiang

doi:10.3892/etm.2016.3887

Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver

Authors:
- Maoqin Li
- Jingxi Sun
- Jiaqiong Li
- Zaixiang Shi
- Jiyuan Xu
- Bo Lu
- Shuli Cheng
- Yanjun Xu
- Xiaomeng Wang
- Xianjiang Zhang
View Affiliations

Affiliations: Department of Intensive Care Unit, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou Clinical School of Xuzhou Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu 221009, P.R. China
Published online on: November 8, 2016 https://doi.org/10.3892/etm.2016.3887
Pages: 3873-3876
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical efficacy and safety of different combinations of non-bio artificial liver in the treatment of acute liver failure was examined. A total of 61 cases were selected under blood purification treatment from the patients with severe acute liver failure admitted to the severe disease department of the hospital from December, 2010 to December, 2015. Three types of artificial liver combinations were observed, i.e., plasma exchange plus hemoperfusion plus continuous venovenous hemodiafiltration (PE+HP+CVVHDF), PE+CVVHDF and HP+CVVHDF. The heart rate (HR), mean arterial pressure (MAP), respiratory index (PaO2/FiO2), liver and kidney function indicator, as well as platelet and coagulation function were compared. A comparison before and after the treatment using the three methods, showed improvement in the HRs, MAPs, PaO2/FiO2, total bilirubins (TBIL) and alanine aminotransferases (ALT) (P<0.05), of which TBIL and ALT were decreased more significantly (P<0.01) in the PE+CVVHDF and PE+HP+CVVHDF groups. Only changes in the PE+HP+CVVHDF and PE+CVVHDF groups were statistically significant after prothrombin time and albumin treatment (P<0.05). The difference between the decrease in TBIL in the PE+HP+CVVHDF group and that in the HP+CVVHDF group was statistically significant (P<0.05). Treatment of the 61 patients using the artificial liver support system yielded a survival rate of 62.3% (38/61), and a viral survival rate of 35.0% (7/20); with the non-viral survival rate being 75.6% (31/41). In conclusion, following the treatment of three types of artificial livers, the function was improved to varying degrees, with the PE+HP+CVVHDF and the PE+CVVHDF method being better. By contrast, after the treatment of non-viral liver failure, the survival rate was significantly higher than the patients with viral liver failure.

View Figures

View References

1	McPhail MJW, Kriese S and Heneghan MA: Current management of acute liver failure. Curr Opin Gastroenterol. 31:209–214. 2015. View Article : Google Scholar : PubMed/NCBI
2	Stadlbauer V, Davies NA, Sen S and Jalan R: Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis. 28:96–109. 2008. View Article : Google Scholar : PubMed/NCBI
3	Catalina-Rodríguez MV and Bañares-Cañizares R: Artificial liver support systems: update on albumin dialysis (MARS). Gastroenterol Hepatol. 28:453–460. 2005.(In Spanish). View Article : Google Scholar : PubMed/NCBI
4	Ting PP and Demetriou AA: Clinical experience with artificial liver support systems. Can J Gastroenterol. 14:(Suppl D). 79D–84D. 2000. View Article : Google Scholar : PubMed/NCBI
5	Kjaergard LL, Liu J, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 289:217–222. 2003. View Article : Google Scholar : PubMed/NCBI
6	Liu J, Kjaergard LL, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. Liver. 22:433–438. 2002. View Article : Google Scholar : PubMed/NCBI
7	Sadahiro T, Hirasawa H, Oda S, Shiga H, Nakanishi K, Kitamura N and Hirano T: Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure. Crit Care Med. 29:1386–1392. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bektas M, Idilman R, Soykan I, Soydan E, Arat M, Cinar K, Coban S, Tuzun A, Bozkaya H, Ormeci N, et al: Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. J Clin Gastroenterol. 42:517–521. 2008. View Article : Google Scholar : PubMed/NCBI
9	Biancofiore G, Bindi LM, Urbani L, Catalano G, Mazzoni A, Scatena F, Mosca F and Filipponi F: Combined twice-daily plasma exchange and continuous veno-venous hemodiafiltration for bridging severe acute liver failure. Transplant Proc. 35:3011–3014. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shi D: Advances in the treatment of acute liver failure. Chinese J Critical Care Med. 33:92–94. 2013.(In Chinese).
11	Li M, Li J and Shi Z: Clinical research on the treatment of the patients with non-viral acute liver failure by different combinations of non-biologic artificial liver. Chinese J Emergency Med. 23:1198–1120. 2014.(In Chinese).
12	Komura T, Taniguchi T, Sakai Y, Yamashita T, Mizukoshi E, Noda T, Okajima M and Kaneko S: Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure. J Gastroenterol Hepatol. 29:782–786. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ye WJ, Li LJ, Yu HY, Zhang XP, Tian J and Bai MH: Clinical research of plasma exchange with continuous veno-venous hemofiltration in treating mid- and late-stage chronic severe viral hepatitis B patients. Chinese J Hepatol. 13:370–373. 2005.(In Chinese).
14	He CS, Shi W, Ye ZM, Liang XL, Zhang B, Liu SX and Qin TH: Efficacy and safety of coupled plasma filtration adsorption combined with continuous veno-venous hemofiltration for multiple organ dysfunction syndrome patients with acute liver failure. Chinese Critical Care Med. 19:47–49. 2007.(In Chinese).
15	Liu Y, He J, Che D and Yang W: The treatment of liver function failure and multi-organ dysfunction syndrome by artificial liver support system. Chinese Critical Care Medicine. 8:431–432. 2006.(In Chinese).
16	Hepatic failure diagnosis and treatment guideline. Chinese J Hepatol. 14:543–646. 2006.
17	Ye W, Jin J, Yu H and Wang J: Therapeutic effects of blood purification in 160 cases with liver failure. Chinese J Integrated Traditional and Western Medicine in Intensive and Critical Care. 13:370–372. 2006.(In Chinese).
18	Arjuna Singanayagam and William Bernal: Update on acute liver failure. Curr Opin Crit Care. 21:134–141. 2015. View Article : Google Scholar : PubMed/NCBI
19	Luo L, Yuan CL, Zeng WQ and Zhang DZ: Treatment of severe hepatitis by HA neutral macroporous resin hemoperfusion: an analysis of 40 cases. World Chinese J Digestol. 16:2533–2536. 2008.(In Chinese). View Article : Google Scholar
20	Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, Sherwood R, Wendon JA and Bernal W: Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 34:42–48. 2014. View Article : Google Scholar : PubMed/NCBI